Endocrinology and Metabolic CRO Services for Complex Clinical Trials
Full-service clinical trial delivery plus integrated clinical trial technology for biopharma sponsors developing therapies in obesity, diabetes, MASH, dyslipidemia, and rare endocrine disorders.
Endocrine and metabolic programs often require tight coordination across biomarker-driven eligibility, dose titration, background standard-of-care management, device and lab data flows, and longitudinal endpoint collection. Sitero brings together therapeutic execution, biometrics, medical oversight, safety, and connected systems to reduce operational friction from start-up through database lock.
Built for Endocrine and Metabolic Complexity
Metabolic and endocrine studies can be operationally demanding long before the first participant is randomized. Eligibility criteria may depend on biomarker thresholds, prior therapy exposure, comorbidities, rescue-medication rules, and background standard of care, while endpoint packages often span central labs, connected devices, ePRO, imaging, and repeated site visits over extended durations.
These realities create pressure across startup, site execution, data review, and retention. A more integrated operating model can help sponsors reduce handoffs across clinical operations, medical monitoring, safety, biometrics, and trial technology while maintaining clearer ownership across the study lifecycle.
Connected technology for metabolic and endocrine trial execution
Metabolic and endocrine studies generate complex longitudinal data from labs, devices, ePRO, and repeated visits. When systems come from multiple vendors, each change can add delay and reconciliation effort. Sitero delivers metabolic and endocrine trials on Mentor, its proprietary eClinical platform that keeps data and workflows aligned across the study.
Clinical Trial Technology that Supports Execution
Sitero’s delivery model is supported by a broad eClinical ecosystem, including:
Mentor EDC
Integration advantageWhen your metabolic or endocrine protocol adds a new cohort or visit, EDC updates are managed by the same team running your study, rather than a separate third-party vendor and change order.
Mentor RTSM
Integration advantageRTSM and EDC share a common data layer, so stratification factors and key metabolic/endocrine variables are verified at entry rather than reconciled later.
Mentor Site and Participant Payments
Integration advantagePayment triggers run off the same Mentor data your sites are already entering for visits, labs, and procedures, reducing manual reconciliation between EDC, visit logs, and finance systems.
Mentor eConsent
Integration advantageYour Sitero project team and your sponsor team see the same eConsent data in real time, without waiting on transfers between separate systems.
Mentor CTMS and eTMF
Integration advantageYour Sitero project team and your sponsor team see the same operational and TMF data in real time, without waiting for transfers between separate systems.
Mentor Insights and Reporting
Integration advantageOperational and clinical metrics are pulled from a single Mentor data layer across EDC, RTSM, CTMS, and eConsent, so teams align on one source of truth instead of stitching together separate metabolic/endocrine reports.
Endocrinology and Metabolic CRO Services
Sitero supports endocrine and metabolic studies with full-service clinical delivery and specialized functional expertise aligned to chronic-disease protocols, longitudinal endpoint strategies, and high-touch site workflows.
Clinical operations for metabolic studies
Support studies from feasibility and startup through closeout with consistent operational ownership. Core capabilities include country and site strategy, enrollment planning, visit schedule execution, titration workflows, participant retention, and site engagement across academic, community, and specialty endocrine or metabolic networks.
Biometrics for longitudinal endpoint quality
Build clean, analysis-ready datasets for complex metabolic endpoints. Database design, edit checks, derivations, interim review strategy, and statistical planning can be aligned around repeated measures, longitudinal biomarker trends, rescue medication handling, missing-data risk, and protocol-specific endpoint definitions.
Medical monitoring and scientific oversight
Medical oversight is especially important in studies involving glycemic excursions, hypoglycemia risk, hormonal rescue rules, liver enzyme monitoring, cardiovascular comorbidity, and rare endocrine disease presentation. Sitero can align scientific oversight with the realities of chronic-dosing populations and protocol-driven safety decision points.
Drug safety and pharmacovigilance support
Safety operations should maintain visibility across chronic-use, high-comorbidity populations, including tolerability trends, metabolic decompensation, hepatic findings, cardiovascular events, and endocrine-specific adverse events. Integrated safety workflows can help sponsors monitor data consistently across long-duration studies and multi-country programs.
IRB, ethics, and governance support
Support ethics workflows, protocol amendments, informed consent updates, and specialized committee or oversight requirements while reducing administrative drag for sponsors and sites.
Sitero Key Metrics
Integrated workflows for lower site burden and clearer oversight
In metabolic clinical development, operational pressure rarely sits in one function alone. Site burden often increases when labs, devices, ePRO, dosing logistics, participant communication, data review, and safety monitoring are managed through disconnected processes.
A connected model can help sponsors simplify execution across sites and internal teams by reducing unnecessary handoffs and creating better operational visibility. That can be especially valuable in obesity, diabetes, and MASH studies where long treatment periods, repeated assessments, and participant adherence have a direct effect on data completeness and trial momentum.
Global support for metabolic and endocrine programs
Sitero supports endocrinology and metabolic studies across a broad international footprint, helping sponsors manage global execution with consistent oversight and deliver across diverse indications.
Why Sponsors Choose Sitero for Endocrinology & Metabolic Trials
Sponsors typically select Sitero when they need:
A partner that can cover operational execution plus enabling systems
Clear ownership and predictable delivery for lean sponsor teams
Broad functional capabilities beyond a single product or point solution
Global support without unnecessary complexity
FAQs
Talk to a Trial Expert
Advance complex endocrine and metabolic studies with an integrated CRO and technology partner
From obesity and diabetes to MASH and rare endocrine disorders, Sitero supports complex clinical development with full-service delivery and connected trial technology designed to reduce operational friction and improve study visibility.
